Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Cartesian Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
selectabio.comAI Executive Summary
AI-powered analysis of 8-K filing content
Cartesian Therapeutics announced additional retreatment data from its Phase 2 trial of Descartes-08 for myasthenia gravis, providing new efficacy insights that could influence treatment protocols and future commercialization strategies.
Key Takeaways
Phase 2 trial data for Descartes-08 in myasthenia gravis patients has been released with focus on retreatment outcomes
The announcement represents a significant development milestone in the company's therapeutic pipeline for MG treatment
1 more takeaway
Filing Overview
What This Means
Cartesian Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.